Synthesis, in vitro anticancer activity, and pharmacokinetic profiling of the new tetrahydropyrimidines: Part I
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400403 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Emilija Milović und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sciences, Institute for Information Technologies Kragujevac, University of Kragujevac, Kragujevac, Serbia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Molecular Docking Simulation, Pyrimidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Ministry of Science, Technological Development, and Innovation of the Republic of Serbia, APV Provincial Secretariat for Higher Education and Scientific Research.
Abstract (Originalsprache)
Different vanillin‐based aldehydes were used to synthesize novel tetrahydropyrimidines (THPMs) via conventional Biginelli reaction. The THPMs were tested against human normal cells (MRC‐5) and cancer cell lines (HeLa, K562, and MDA‐MB‐231). With IC 50 values of 10.65, 10.70, and 12.76 µM, compounds 4g , 4h , and 4i exerted the strongest cytotoxic effects against K562 cells. The best activity was achieved for 4g on MDA‐MB‐231 cells (IC 50 = 9.20 ± 0.14 µM). The effects of compounds 4g , 4h , and 4i on the cell‐cycle phase distribution of K562 cells were analyzed. Principal component analysis was carried out for the chemometrics analysis to comprehend the relationship between the anticancer activity of the THPMs, pharmacokinetic properties, and partition coefficients, as well as the relationship between the chromatographic behavior and retention parameters. The highest retention rates are found for molecules 4g , 4h , and 4i , which have the longest carbon chains, indicating that the length of the alkyl chain positively affects the molecule's anticancer activity but only if the number of carbon atoms is not higher than seven. Additionally, molecular docking analysis was performed to determine the preferred binding modes of the investigated ligands ( 4g , 4h , and 4i ) with a DNA dodecamer and bovine serum albumin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Sciences, Institute for Information Technologies Kragujevac, University of Kragujevac, Kragujevac, Serbia.
- Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
- Institute of Meat Hygiene and Technology, Belgrade, Serbia.
- Department of Chemistry, Faculty of Science, University of Kragujevac, Kragujevac, Serbia.
- Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
- Department for Neuroendocrine Tumors and Hereditary Cancer Syndromes, Diabetes and Metabolic Diseases, Medical School, Clinic for Endocrinology, University of Belgrade, Belgrade, Serbia.
ORCID-Profile: Emilija Milović
Förderung
- Ministry of Science, Technological Development, and Innovation of the Republic of Serbia
- APV Provincial Secretariat for Higher Education and Scientific Research
Zitieren
APA
Milović, E., Ristovski, J. T., Stefanović, S., Petronijević, J., Joksimović, N., Matić, I. Z., Đurić, A., Ilić, B., Klisurić, O., Radan, M., Nikolić, K., & Janković, N. (2024). Synthesis, in vitro anticancer activity, and pharmacokinetic profiling of the new tetrahydropyrimidines: Part I. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400403
Vancouver
Milović E, Ristovski JT, Stefanović S, Petronijević J, Joksimović N, Matić IZ, et al. Synthesis, in vitro anticancer activity, and pharmacokinetic profiling of the new tetrahydropyrimidines: Part I. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400403
BibTeX
@article{Milovi2024,
author = {Milović, Emilija and Ristovski, Jovana Trifunović and Stefanović, Srđan and Petronijević, Jelena and Joksimović, Nenad and Matić, Ivana Z and Đurić, Ana and Ilić, Bojana and Klisurić, Olivera and Radan, Milica and Nikolić, Katarina and Janković, Nenad},
title = {Synthesis, in vitro anticancer activity, and pharmacokinetic profiling of the new tetrahydropyrimidines: Part I},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400403}
}
EUVIMED